An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 After a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients With Advanced Solid Tumor Malignancies.
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Vadimezan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Apr 2016 Status changed from completed to discontinued.
- 10 Feb 2011 New trial record